A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

Phase 1 part of the study will consist of a dose-escalation and a dose-finding component . Phase 2 will enroll subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma, who have failed all standard therapies or for whom standard therapy does not exist, into 8 groups: Group 1: Endometrial or Ovarian cancer Group 2: Biliary tract cancer Group 3: HCC Group 4: Breast cancer, meeting any of the following criteria: * HER-2 refractory MBC * HR positive, HER-2 negative, MBC post-CDK4/6 inhibitor * Triple-negative breast cancer (TNBC) Group 5: B-cell lymphoma Group 6: T-cell lymphoma (CTCL and PTCL) Group 7: mCRC, including KRAS mutated mCRC Group 8: Basket cohort: Tumor types suspected to have a related mechanism of action such as MCL1, MYC or CCNE amplification/overexpression not included in previous groups.